These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3803417)

  • 1. Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial.
    Ball MJ; Vella M; Rechlass JP; Jones DB; Stirling C; Mann JI; Galton D
    Eur J Clin Pharmacol; 1986; 31(2):201-4. PubMed ID: 3803417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP
    Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperlipidaemia with acipimox.
    Lintott CJ; Scott RS; Bremer JM
    Curr Med Res Opin; 1989; 11(6):374-9. PubMed ID: 2707049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
    Taskinen MR; Nikkilä EA
    Atherosclerosis; 1988 Feb; 69(2-3):249-55. PubMed ID: 3279968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia.
    Barlow CW; Soicher ER; Jankelow D; Myburgh DP
    S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
    Hadigan C; Liebau J; Torriani M; Andersen R; Grinspoon S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4438-44. PubMed ID: 16940448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
    Shih KC; Kwok CF; Hwu CM; Hsiao LC; Li SH; Liu YF; Ho LT
    Diabetes Res Clin Pract; 1997 May; 36(2):113-9. PubMed ID: 9229195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.
    Crepaldi G; Avogaro P; Descovich GC; Di Perri T; Postiglione A; Sirtori CR; Strano A; Ventura S; Musatti L
    Atherosclerosis; 1988 Mar; 70(1-2):115-21. PubMed ID: 3281679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
    Nielsen S; Møller N; Pedersen SB; Christiansen JS; Jørgensen JO
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
    Vaag AA; Beck-Nielsen H
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.